GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02564692 |
Recruitment Status :
Recruiting
First Posted : October 1, 2015
Last Update Posted : June 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Alzheimer Disease |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 500000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 15 Years |
Official Title: | Alzheimer's Prevention Registry GeneMatch Program |
Study Start Date : | November 2015 |
Estimated Primary Completion Date : | December 2030 |
Estimated Study Completion Date : | December 2030 |

- Number of individuals who enroll in GeneMatch [ Time Frame: 15 years ]
- Number of individuals referred to research studies [ Time Frame: 15 years ]
- Number of individuals who enroll in research studies [ Time Frame: 15 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age 50-90, inclusive
- Provide basic demographic, medical history, and contact information
- Consent to APOE genotyping without receiving results
- Live in the United States
Exclusion Criteria:
- Unable to comply with this project's protocol requirements
- Self-reported diagnosis of dementia or any other objective cognitive impairment syndrome

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564692
Contact: David Gordon, MS | 1-888-STOP-ALZ | GeneMatch@endALZnow.org |
United States, Arizona | |
Banner Alzheimer's Institute | Recruiting |
Phoenix, Arizona, United States, 85006 | |
Contact: David Gordon GeneMatch@endalznow.org | |
Principal Investigator: Jessica B Langbaum, PhD |
Principal Investigator: | Jessica B Langbaum, PhD | Banner Alzheimer's Institute |
Publications of Results:
Responsible Party: | Jessica Langbaum, PhD, Director, Alzheimer's Prevention Initiative, Banner Health |
ClinicalTrials.gov Identifier: | NCT02564692 |
Other Study ID Numbers: |
APR-001 |
First Posted: | October 1, 2015 Key Record Dates |
Last Update Posted: | June 8, 2021 |
Last Verified: | June 2021 |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |